Indian officials balk at Mylan's Agila buyout; Hikma hikes 2013 forecast; Promo-makers fight pharma ban in EU;

 @FiercePharma: Cost watchdogs veto Novartis breast cancer med Afinitor. NICE says "disappointed" data isn't stronger. News | Follow @FiercePharma

> Indian officials put the brakes on Mylan's ($MYL) plan to buy Strides Arcolab's injectables unit Agila Specialties, deferring approval of the deal for now. Report

> Jordan's Hikma Pharmaceuticals hiked its 2013 forecast, now expecting 17% sales growth thanks to strong sales of a generic antibiotic; its shares rose on the news. Report

> Manufacturers of promotional products--such as logo-bearing pens and sticky notes--are complaining to European officials about the pharma industry's choice to ban them next year. Report

> Novartis ($NVS) joined forces with Biological E, an Indian vaccinemaker, to deliver its typhoid and paratyphoid vaccinations to a set of new countries. Report

> GW Pharmaceuticals said it launched its cannabinoid drug Sativex in Italy. Report

> UCB outlicensed a rheumatoid arthritis drug candidate to Russia's R-Pharm to sell it in Russia and abroad. Report

Medical Device News

 @FierceMedDev: Roche chases FDA cancer indication for HPV diagnostic. Story | Follow @FierceMedDev

 @MarkHFierce: Duke has found early promise with a blood Dx  that predicts aspirin treatment success. Report | Follow @MarkHFierce

 @DamianFierce: Patient lawsuits mount as India tries to crack down on unethical clinical trials. Item | Follow @DamianFierce

> Alere heads toward proxy fight as activist investor ups ante. Article

> Nikon mulls entry into medical devices business. Story

> Crescendo Bioscience achieves Medicare coverage for RA Dx. News

Biotech News

 @FierceBiotech: SEC hunting down traders who made a quick killing on Onyx shares. Report | Follow @FierceBiotech

 @JohnCFierce: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown. News | Follow @JohnCFierce

 @RyanMFierce: For those of you who remember Son of Lantus, watch out for Lantus' fraternal (not identical) twin from Lilly and Boehringer. | Follow @RyanMFierce

 @EmilyMFierce: Cholera is altering the human genome. Story | Follow @EmilyMFierce

> Swiss biotech OncoEthix snags $19M round to back leukemia drug study. More

> Cytokinetics shares slide on dosing snafu in ALS drug study. Article

> Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown. Story

CRO News

> Report: Academia could better use CROs for early research. News

> Lawsuits mount as India pushes trial reforms. Article

> CRO Blue Sky taps new CEO amid growth. Story

> Parexel teams with Rutgers for clinical trials. More

> CROs shift as early-phase demand dries up. News

Biotech IT News

> Report: Pharma execs warm to med reminder apps. News

> GE, Accenture back analytics provider in $20M financing. Article

> Bioinformatics gives U. Wisconsin team an 'edge' in cystic fibrosis study. Story

> AstraZeneca snaps up drug-discovery software from Cambridge startup. More

> Facebook, Twitter bolster Canadian biotech's research of Crohn's therapy. News

And Finally... New clinics are targeting pregnant women addicted to prescription painkillers to help them quit. Report (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.